title: Secukinumab (AIN-457) for the treatment of Psoriasis.
abstract: Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.
authors.affiliation: a Department of Dermatology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Tarannum
authors.initials: T
authors.lastname: Jaleel
authors.affiliation: a Department of Dermatology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Craig
authors.initials: C
authors.lastname: Elmets
authors.affiliation: c University of California San Diego School of Medicine , La Jolla , CA , USA.
authors.forename: Allison
authors.initials: A
authors.lastname: Weinkle
authors.affiliation: b University of Alabama School of Medicine , Birmingham , AL , USA.
authors.forename: Sama
authors.initials: S
authors.lastname: Kassira
authors.affiliation: a Department of Dermatology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Boni
authors.initials: B
authors.lastname: Elewski
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; C508717:IL17A protein, human; D020381:Interleukin-17; C555450:secukinumab
keywords: AIN-457; IL-17; Th 17; pharmacology; psoriasis; secukinumab